-
Top-notch execution is letting Home Depot thrive
-
Roche has one of the best long-term growth profiles in the Big Pharma space
-
Actavis gets a very useful asset, while Warner Chilcott shareholders get a decent ...
-
Websense gets a fair deal, given its ongoing growth problems.
-
Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
-
Campbell Soup remains volatile, but investors haven't minded
-
A big rally has brought Pfizer back to fair value.
-
Tumblr is a high-potential asset, but Yahoo! absolutely must execute.
-
Sluggish sales growth at Wal-Mart isn't a big surprise, but it could keep a lid on ...
-
The spectre of share loss to Cisco has become real.
-
Applied Materials is showing progress, but has the 50% recovery already anticipated ...
-
Autodesk comes up short again as the macro environment stays soft.
-
Brocade badly needs to prove that it can grow again.
-
Kohl's did okay by the analysts, but core operating trends here certainly aren't ...
-
Cisco comes through with a quarter that should calm tech investors.
-
Though Deere's shares sold off after earnings, the business model is sound and rolling ...
-
Cummins is still bottoming, but the Street is already thinking recovery
-
Core operating performance at Agilent needs to improve
-
Even with its problems and challenges, BP seems too cheap today
-
Valspar's market share and performance suggest the stock has recovered far enough.
-
Weak traffic isn't worrying investors who still prize Chipotle's mid-teens operating ...
-
Danaher won't stay stuck for long.
-
Roper's organic growth isn't great now, but the market's love for this M&A frequent ...
-
BorgWarner has intriguing growth prospects, but the shares have already recovered ...
-
ABB is executing well in a tough environment, but losing CEO Hogan is a big blow
-
AEIS is cyclically down, but far from out.
-
Eaton should see very solid growth from here, but the market is already expecting ...
-
Yum! Brands' shares have rebounded pretty well despite an ongoing stream of bad news ...
-
Middleby continues to gain share and expand its market opportunities in an under-innovative ...
-
ArcelorMittal looks too cheap, but it could be a long wait to see it really outperform
-
Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
-
Investors aren't sold on Nvidia's strategy, and that shows in the stock price.
-
Teva's partnership with Alexza looks like an expensive gamble.
-
Absent a real competitive moat, it's hard to make sense of Rackspace's valuation.
-
Groupon still has a lot of work to do to reassure the Street that this business model ...
-
Will Microsoft pay up to take Nook Media off Barnes & Noble's hands?
-
More questions about the real efficacy of fish oil is bad news for Amarin.
-
Are investors going to get scalded by this Starbucks-Green Mountain deal?
-
After a big quarterly miss, can investors afford to trust the long-term opportunity ...
-
Emerson's relative performance may be positive, but the net value is still lacking
-
Investors seem to bullish on Mondelez, given the relative performance at Kellogg ...
-
Disney comes through again, but valuation is getting pretty high.
-
Macro pressures are outweighing solid internal progress at Hologic.
-
Amgen really needs the pipeline to come through to support this valuation.
-
Whole Foods carries rich multiples, but the growth seems to justify it
-
Analysts are projecting a big turnaround in Johnson Controls' margins, but that the ...
-
Broadcom has multiple appealing growth opportunities, but also competitive challenges ...
-
Sysco seems to be trading more on reputation than reality today.
-
WIthout stronger construction markets, Ingersoll-Rand's turnaround could bog down
-
BMC's sluggish growth results in a takeout bid that doesn't seem to fully value the ...
Free Annual Reports
